Thalidomide therapy in refractory solid tumour patients [9]

British Journal of Haematology

Volumn 110, Issue 3, 2000, Pages 754-

  Gutheil, J ^a   Finucane, D ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

End stage cancer; Myeloma; Refractory; Thalidomide

Indexed keywords

THALIDOMIDE;

ADULT; AGED; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; LETTER; MALE; MYELOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; MALE; MIDDLE AGE; MULTIPLE MYELOMA; NEOPLASMS; PALLIATIVE CARE; THALIDOMIDE; TREATMENT FAILURE;

EID: 0033772376     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02239-11.x     Document Type: Letter

References (4)

1. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells
2. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
3. Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug
4. Antitumor activity of thalidomide in refractory multiple myeloma